Regentys will partner with Cook Biotech to develop a novel treatment for ulcerative colitis. Under the terms of a signed letter of intent, Cook Biotech will develop and manufacture Regentys’ licensed clinical product, ECMH Rectal Solution (Extracellular Matrix Hydrogel), which will be used in first-in-man clinical studies conducted by Regentys in 2018. As part of the partnership, Cook Biotech has become a stakeholder in Regentys.   “We are excited to partner with a world-class org...